Answers are grounded in this paper and cite their sources.
Publication of the ARRIVE trial was associated with an increase in elective induction, and no change in cesarean birth or hypertensive disorders of pregnancy in singleton nulliparous patients giving birth at 39 weeks or later. There was a flattening of the pre-ARRIVE decreasing trend in perinatal adverse events.
No takes yet. Share an insight, caveat, or question.
Nethery et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: